1/25
08:33 pm
espr
How The New Price Target Is Shaping The Story For Esperion Therapeutics (ESPR) [Yahoo! Finance]
Medium
Report
How The New Price Target Is Shaping The Story For Esperion Therapeutics (ESPR) [Yahoo! Finance]
1/11
06:00 pm
espr
Esperion Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
Medium
Report
Esperion Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
1/5
08:40 am
espr
Esperion to Participate in Upcoming 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Low
Report
Esperion to Participate in Upcoming 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
1/5
08:00 am
espr
Esperion to Participate in Upcoming 44th Annual J.P. Morgan Healthcare Conference
Low
Report
Esperion to Participate in Upcoming 44th Annual J.P. Morgan Healthcare Conference
1/3
01:06 am
espr
Esperion Therapeutics (NASDAQ:ESPR) was upgraded by analysts at
Wall Str
Low
Report
Esperion Therapeutics (NASDAQ:ESPR) was upgraded by analysts at
Wall Str
12/19
08:00 am
espr
Esperion’s Bempedoic Acid Receives Recommendation in 2025 ACC Scientific Statement on Management of Peripheral Artery Disease in Adults With Diabetes
Low
Report
Esperion’s Bempedoic Acid Receives Recommendation in 2025 ACC Scientific Statement on Management of Peripheral Artery Disease in Adults With Diabetes
12/9
07:36 pm
espr
Why The Narrative Around Esperion Therapeutics Is Shifting After Analyst Upgrades And Trial Results [Yahoo! Finance]
Low
Report
Why The Narrative Around Esperion Therapeutics Is Shifting After Analyst Upgrades And Trial Results [Yahoo! Finance]
12/9
04:30 pm
espr
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Low
Report
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
11/26
06:43 am
espr
Esperion Therapeutics (NASDAQ:ESPR) was upgraded by analysts at Piper Sandler to a "strong-buy" rating.
Medium
Report
Esperion Therapeutics (NASDAQ:ESPR) was upgraded by analysts at Piper Sandler to a "strong-buy" rating.
11/25
09:19 am
espr
Esperion Therapeutics (NASDAQ:ESPR) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $9.00 price target on the stock.
High
Report
Esperion Therapeutics (NASDAQ:ESPR) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $9.00 price target on the stock.
11/25
09:16 am
espr
Why Analysts Are Rewriting Esperion's Story After New Pipeline Results and Global Partnerships [Yahoo! Finance]
Low
Report
Why Analysts Are Rewriting Esperion's Story After New Pipeline Results and Global Partnerships [Yahoo! Finance]
11/21
08:00 am
espr
Esperion Partner Otsuka Launches NEXLETOL® in Japan for the Treatment of Hypercholesterolemia
Medium
Report
Esperion Partner Otsuka Launches NEXLETOL® in Japan for the Treatment of Hypercholesterolemia
11/19
08:00 am
espr
Esperion to Participate in Piper Sandler 37th Annual Healthcare Conference
Low
Report
Esperion to Participate in Piper Sandler 37th Annual Healthcare Conference
11/18
08:01 am
espr
Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease [Yahoo! Finance]
Low
Report
Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease [Yahoo! Finance]
11/18
07:00 am
espr
Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease
Low
Report
Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease
11/12
09:07 am
espr
Esperion Therapeutics (NASDAQ:ESPR) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
Low
Report
Esperion Therapeutics (NASDAQ:ESPR) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
11/12
08:06 am
espr
Esperion Therapeutics (NASDAQ:ESPR) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..
Low
Report
Esperion Therapeutics (NASDAQ:ESPR) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..
11/11
02:12 am
espr
Esperion Therapeutics: Biotech With Limited Upside, Hold [Seeking Alpha]
Medium
Report
Esperion Therapeutics: Biotech With Limited Upside, Hold [Seeking Alpha]